Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

After treatment method for attenuated strain polio inactivated vaccine

A polio and inactivated vaccine technology, applied in the field of post-processing of attenuated polio inactivated vaccines, can solve problems such as inability to meet large-scale production and inability to process virus liquid, and achieve safety and immunogenicity Good, stable and reliable quality, good repeatability

Active Publication Date: 2005-05-18
INST OF MEDICAL BIOLOGY CHINESE ACAD OF MEDICAL SCI
View PDF0 Cites 10 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, conventional methods can neither meet the needs of large-scale production nor handle large-scale production of virus fluids. Therefore, it is necessary to improve the existing technology

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0021] 1. Clarification: 350 liters of virus fluid cultured in a 550-liter fermenter was filtered and clarified through a three-stage filter column with a pore size of 0.75 μm, 0.45 μm, and 0.22 μm to remove cell debris and impurities in the virus fluid and maintain the purity of the virus fluid. sterile state;

[0022] 2. Concentration: Concentrate the clarified virus liquid to 1.4 liters with a 100,000 molecular weight cut-off ultrafiltration membrane in Millipore cross-flow ultrafiltration equipment;

[0023] 3. Purification:

[0024] A, gel filtration: in the Phamacia Index70 chromatographic column, install Sepharose CL-6B chromatographic filler, flush with 80mmol / L phosphate buffer (pH7.0), get the virus concentrate, add in the chromatographic column, Elute with 80mmol / L phosphate buffer (pH7.0), measure the absorbance at an ultraviolet absorption wavelength of 280, and collect about 600 ml of the first peak (virus peak);

[0025] B. Ion exchange: In the Phamacia Index1...

Embodiment 2

[0029] 1. Clarification: 350 liters of virus fluid cultured in a 550-liter fermenter was filtered and clarified through a three-stage filter column with a pore size of 1.0 μm, 0.6 μm, and 0.45 μm to remove cell debris and impurities in the virus fluid and maintain the purity of the virus fluid. sterile state;

[0030] 2. Concentration: Concentrate the clarified virus liquid to 1.4 liters with a 100,000 molecular weight cut-off ultrafiltration membrane in Millipore cross-flow ultrafiltration equipment;

[0031] 3. Purification:

[0032] A, gel filtration: in the Phamacia Index70 chromatographic column, install Sepharose CL-6B chromatographic filler, flush with 80mmol / L phosphate buffer (pH7.2), get virus concentrate, add in the chromatographic column, Elute with 80mmol / L phosphate buffer (pH7.2), measure the absorbance at an ultraviolet absorption wavelength of 280, and collect about 600 ml of the first peak (virus peak);

[0033] B. Ion exchange: In the Phamacia Index100 chr...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The present invention is after-treatment process of deactivated vaccine of attenuated polio strain. The large scale cultured virus liquid is three stage filtered in filtering columns of 06-1.0 micron, 0.45-0.6 micron and 0.22-0.45 micron pore size separately, clarified, ultrafiltered and concentrated, chromatographic column purified and deactivated to obtain semi-finished vaccine product with high purity, good immunogenicity, high safety and stable quality for the requirement of producing the attenuated polio strain. The semi-finished vaccine product can meet the requirement of product and may be used to produce Aabin IPV vaccine with stable quality, high safety and excellent immunogenicity.

Description

technical field [0001] The invention relates to a post-processing method of an attenuated strain of inactivated polio vaccine, belonging to medical biology [0002] technology field. Background technique [0003] Poliomyelitis is an acute infectious disease caused by poliovirus types I, II, and III, which is widely spread and extremely harmful. The clinical symptoms cause flaccid paralysis of muscles, especially limbs, which mostly occurs in children, so it is also called "poliomyelitis". Before the advent of the vaccine, the disease was prevalent all over the world. At that time, the incidence rate in my country was 3.18 / 100,000. In the middle and late 1950s, two scientists in the United States, Dr. Salk and Dr. Sabin, successively successfully developed inactivated polio vaccine (IPV) and oral polio vaccine (OPV), thereby preventing and eradicating spinal cord for human beings. Polio provides a powerful weapon. Practice has proved that both vaccines are safe and effect...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K39/13A61P31/14C12N7/04
CPCY02A50/30
Inventor 褚嘉祐姜述德孙明波廖国阳张丽旌李卫东俞泳霆李平忠
Owner INST OF MEDICAL BIOLOGY CHINESE ACAD OF MEDICAL SCI
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com